Haemonetics Corporation (HAE)

Solvency ratios

	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019
Debt-to-assets ratio	0.36	0.39	0.37	0.38	0.39	0.40	0.41	0.42	0.30	0.35	0.39	0.43	0.38	0.22	0.21	0.21	0.24	0.25	0.26	0.25
Debt-to-capital ratio	0.45	0.48	0.46	0.46	0.48	0.49	0.51	0.50	0.43	0.46	0.50	0.53	0.49	0.29	0.31	0.33	0.34	0.35	0.35	0.35
Debt-to-equity ratio	0.83	0.91	0.84	0.87	0.92	0.98	1.04	0.99	0.75	0.87	1.00	1.13	0.94	0.41	0.44	0.49	0.52	0.54	0.54	0.54
Financial leverage ratio	2.29	2.33	2.25	2.27	2.37	2.42	2.56	2.36	2.48	2.51	2.58	2.65	2.49	1.83	2.12	2.35	2.16	2.15	2.04	2.13

Haemonetics Corporation's solvency ratios provide insights into the company's ability to meet its long-term financial obligations. The debt-to-assets ratio has shown a fluctuating trend over the periods observed, ranging from 0.22 to 0.43. This ratio indicates that, on average, 36% to 43% of the company's assets are financed by debt.

The debt-to-capital ratio has also displayed variability, fluctuating between 0.29 and 0.53. This metric reveals how much of the company's capital structure is funded by debt, with values ranging from 29% to 53%.

The debt-to-equity ratio has shown a similar fluctuating pattern, varying from 0.41 to 1.13. This ratio reflects the proportion of the company's financing that comes from debt versus equity, indicating values between 41% and 113%.

The financial leverage ratio, which provides an overall view of the company's capital structure, has ranged from 1.83 to 2.65. This ratio indicates the company's reliance on debt to finance its operations, with values ranging from 1.83 to 2.65 times its equity.

Overall, the fluctuating trends in these solvency ratios suggest that Haemonetics Corporation has experienced changes in its capital structure and debt levels over the periods analyzed. It is important for investors and stakeholders to monitor these ratios to assess the company's ability to manage its long-term financial obligations effectively.

Coverage ratios

	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019
Interest coverage	8.46	11.91	11.72	13.73	12.00	32.63	30.78	19.74	13.92	3.49	4.13	5.69	5.38	11.66	9.36	8.28	6.38	7.13	6.34	5.26

The interest coverage ratio for Haemonetics Corporation has shown variability over the past few quarters. The ratio measures the company's ability to meet its interest obligations based on its earnings before interest and taxes (EBIT). A higher interest coverage ratio indicates a stronger ability to cover interest expenses.

As of March 31, 2024, Haemonetics Corporation's interest coverage ratio stands at 8.46, indicating that the company generated 8.46 times the earnings needed to cover its interest expenses for that period. This ratio has decreased from the previous quarter but remains at a level that suggests the company is comfortably meeting its interest payment obligations.

Overall, the fluctuations in Haemonetics Corporation's interest coverage ratio over the historical quarters could be influenced by various factors such as changes in interest rates, the level of debt in the company's capital structure, and the company's profitability. It is important for investors and analysts to monitor this ratio over time to assess the company's financial health and ability to service its debt.